{"id":"NCT05629962","sponsor":"Atea Pharmaceuticals, Inc.","briefTitle":"SUNRISE-3: Efficacy and Safety of Bemnifosbuvir in High-Risk Outpatients With COVID-19","officialTitle":"A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Bemnifosbuvir in High-Risk Outpatients With COVID-19","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2022-11-25","primaryCompletion":"2024-04-25","completion":"2024-05-30","firstPosted":"2022-11-29","resultsPosted":"2025-06-13","lastUpdate":"2025-06-13"},"enrollment":2285,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV 2 Infection)","COVID-19"],"interventions":[{"type":"DRUG","name":"Bemnifosbuvir (BEM)","otherNames":["AT-527"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Bemnifosbuvir (BEM)","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of the study is to evaluate whether bemnifosbuvir (BEM) is effective and safe in adults with COVID-19 who do not need to be in the hospital but who are at high risk for progression to severe disease. Eligible subjects will be randomly assigned (by chance) to receive BEM or matching placebo orally for 5 days. Co-administration of locally available standard of care (SOC) is allowed. The total duration of the study is 60 days.","primaryOutcome":{"measure":"Percentage of Subjects Hospitalized for Any Cause or Died Due to Any Cause","timeFrame":"Day 1 through Day 29","effectByArm":[{"arm":"BEM - SCO Stratum","deltaMin":7,"sd":null},{"arm":"PBO - SCO Stratum","deltaMin":2,"sd":null},{"arm":"BEM - Combo Stratum","deltaMin":0,"sd":null},{"arm":"PBO - Combo Stratum","deltaMin":0,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.954"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":9},"locations":{"siteCount":263,"countries":["United States","Argentina","Brazil","Canada","Germany","India","Japan","Latvia","Mexico","Netherlands","Pakistan","Philippines","Romania","South Africa","Spain","Sweden","Tunisia","Turkey (TÃ¼rkiye)","United Kingdom"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":9,"n":1093},"commonTop":["Diarrhoea","Nausea","Hypercholesterolaemia","Hyponatraemia","Dysguesia"]}}